Company intelligence / Profile preview
Shandong Huaxin Pharmaceutical Group
- Ownership
- Private
- Development stage
- Other
Overview
Shandong Huaxin Pharmaceutical Group specializes in the development, manufacturing, and distribution of pharmaceutical preparations including both chemical drugs/APIs/intermediates as well as traditional Chinese medicines. The company has established R&D centers and industrial bases across China. Its portfolio covers a wide range of therapeutic areas with a particular emphasis on anti-tumor agents, anti-infectives, hypoglycemics, respiratory diseases, cardiovascular conditions, digestive health products, dermatology treatments and sedative/tranquilizer formulations. It operates at commercial scale with GMP-compliant facilities.
- Therapeutic areas
- PulmonologyDermatologyGastroenterologyCardiovascularNeurology
- Modalities
- Small moleculeHerbal/Traditional medicineBiologic
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Shandong Huaxin Pharmaceutical Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shandong Huaxin Pharmaceutical Group.